GLPBio

AKIR001

Catalog No.: GC81483Purity:>99.00%
COASDSData Sheet
AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6.

Los productos son exclusivamente para uso en investigación. No aptos para uso humano. No vendemos a pacientes.

AKIR001
1mgIn Stock
$270.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citas (Citations)

Actualmente no hay citas disponibles para este producto. A continuación se muestran publicaciones seleccionadas que citan productos GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Descripción (Description)

AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [ 177 Lu] radiolabeled AKIR001, namely [ 177 Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma [1].

In Vivo, [177Lu]Lu-AKIR001 (5-15 MBq) exhibits dose-dependent efficacy in female BALB/c nu/nu mice with A431 cell xenograft (with complete response rates of 75-80%)[1].

In Vitro, AKIR001 lacks CDC and ADCC activity in BxPC-3 cells[1].

References:
[1]. Mortensen ACL, et al. Preclinical Validation of [ 177 Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials. J Nucl Med. Published online November 6, 2025.

Documentos del producto (Product Documents)

Purity:>99.00%Appearance:A liquid
COASDSData Sheet

Propiedades químicas (Chemical Properties)

Peso molecular
145.48
Almacenamiento
Store at -20°C
Condiciones de envío
Las muestras de evaluación se envían con acumuladores de frío. Los demás tamaños se envían a temperatura ambiente o, previa solicitud, con acumuladores de frío.

Calculadoras (Calculators)Molaridad / Dilución / Peso molecular / Conversión de unidades / Formulación in vivo / Solubilidad

g/mol

Reviews

Review for AKIR001

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%